Africa
Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple sclerosis
Two new analyses from the Phase III TRANSFORMS study presented at the 23rd meeting of the European Neurological Society (ENS) in Barcelona, demonstrated how Novartis’ Gilenya® (fingolimod) was effective against all four key measures of […]